Iovance highlights TIL therapy platform at ESMO Congress
Iovance highlighted its tumor-infiltrating lymphocyte (TIL) cell therapy platform across solid tumors at the 2026 European Society for Medical Oncology Congress.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.